Home » Stocks » AMPE

Ampio Pharmaceuticals, Inc. (AMPE)

Stock Price: $1.79 USD -0.01 (-0.28%)
Updated Jun 24, 2021 3:26 PM EDT - Market open
Market Cap 350.28M
Revenue (ttm) n/a
Net Income (ttm) -14.38M
Shares Out 195.39M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $1.79
Previous Close $1.79
Change ($) -0.01
Change (%) -0.28%
Day's Open 1.81
Day's Range 1.78 - 1.84
Day's Volume 1,007,419
52-Week Range 0.53 - 2.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ENGLEWOOD, Colo., June 18, 2021 /PRNewswire/ – Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for preval...

6 days ago - PRNewsWire

ENGLEWOOD, Colo., June 17, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammato...

1 week ago - PRNewsWire

Best penny stocks to watch with vaccine rates higher than ever The post Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other stocks mentioned: CEI, MUX
1 week ago - PennyStocks

ENGLEWOOD, Colo., June 15, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammato...

1 week ago - PRNewsWire

ENGLEWOOD, Colo., June 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for preva...

1 week ago - PRNewsWire

ENGLEWOOD, Colo., June 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for preva...

1 week ago - PRNewsWire

ENGLEWOOD, Colo., May 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for preval...

1 month ago - PRNewsWire

ENGLEWOOD, Colo., May 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammator...

1 month ago - PRNewsWire

ENGLEWOOD, Colo., May 5, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammator...

1 month ago - PRNewsWire

Ampio Pharmaceuticals Inc (NYSE: AMPE) revealed positive results from its AP-014 Phase 1 trial utilizing inhaled Ampion in treating respiratory distress in COVID-19 patients.  The study met its primary ...

1 month ago - Benzinga

ENGLEWOOD, Colo., April 27, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammat...

1 month ago - PRNewsWire

ENGLEWOOD, Colo., April 27, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammat...

1 month ago - PRNewsWire

ENGLEWOOD, Colo., April 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammat...

2 months ago - PRNewsWire

ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammat...

2 months ago - PRNewsWire

ENGLEWOOD, Colo., April 6, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammato...

2 months ago - PRNewsWire

Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, presented March 24...

2 months ago - Benzinga

ENGLEWOOD, Colo., March 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prev...

2 months ago - PRNewsWire

ENGLEWOOD, Colo., March 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammat...

3 months ago - PRNewsWire

ENGLEWOOD, Colo., March 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammat...

3 months ago - PRNewsWire

Investors liked what they heard in the company's Q4 update.

3 months ago - The Motley Fool

ENGLEWOOD, Colo., March 3, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent infl...

3 months ago - PRNewsWire

ENGLEWOOD, Colo., Feb. 24, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammato...

4 months ago - PRNewsWire

Investors weren't comfortable with FDA feedback on the company's late-stage clinical trial.

5 months ago - The Motley Fool

2020 is almost over. Maybe it's time to cash in -- and cash out?

Other stocks mentioned: BLNK, DNLI, MDB
6 months ago - The Motley Fool

Investors need to pay close attention to Ampio Pharmaceuticals (AMPE) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Ampio Pharmaceuticals, Inc. (AMPE) CEO on Q3 2020 Earnings Results - Conference Call Transcript

7 months ago - Seeking Alpha

If you're itching for a little excitement in your investing, these cheap stocks under $1 might be just what you're looking for. The post 7 Cheap Stocks Under $1 That Deserve A Second Look appeared first...

Other stocks mentioned: GPL, GPOR, GSM, MTNB, TRQ, TRX
8 months ago - InvestorPlace

Ampio’s delayed pivotal phase 3 trial for severe OAK to resume.

9 months ago - Seeking Alpha

These seven penny stocks have the right catalysts, business models, and tailwinds. Read about why the risk is worth it.

Other stocks mentioned: BIOC, BOXL, EMAN
10 months ago - InvestorPlace

Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

Finding The Kink In COVID-19's Armor - Preventing ARDS

Other stocks mentioned: CYDY, GALT, GILD, RHHBY
1 year ago - Seeking Alpha

Ampio (AMPE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

About AMPE

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induce... [Read more...]

Industry
Biotechnology
CEO
Michael Macaluso
Employees
18
Stock Exchange
NYSEAMERICAN
Ticker Symbol
AMPE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for AMPE stock is "Buy" and the 12-month stock price forecast is 4.50.

Price Target
$4.50
Analyst Consensus: Buy